BIOAGE Labs Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters

Nov 06

BIOAGE Labs Inc <bioa.oq> expected to post a loss of 58 cents a share - Earnings Preview </bioa.oq>

BIOAGE Labs Inc BIOA.OQ BIOA.O is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2025
The Emeryville California-based company is expected to report revenue of $1.037 million, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for BIOAGE Labs Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BIOAGE Labs Inc is $9.00, about 17% above its last closing price of $7.47

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jun. 30 2025	-0.46	-0.48	-0.60	Missed	-24.8
Mar. 31 2025	-0.53	-0.53	-0.36	Beat	31.9
Dec. 31 2024	-3.33	-2.08	-1.97	Beat	5.2
Sep. 30 2024	-0.72	-0.72	-6.70	Missed	-828.3

This summary was machine generated November 5 at 21:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581354701"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581354701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581354701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581354701","market":"fut","top_or_hot":-1,"title":"BIOAGE Labs Inc  expected to post a loss of 58 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BIOAGE Labs Inc <bioa.oq> expected to post a loss of 58 cents a share - Earnings Preview </bioa.oq></title></head><body><ul><li><p>BIOAGE Labs Inc <span>BIOA.OQ</span> <span>BIOA.O</span> is expected to  show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2025</p></li><li><p>The Emeryville California-based  company is expected to report revenue of $1.037 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for BIOAGE Labs Inc is for a loss of 58 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 2 \"hold\" and 1 \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for BIOAGE Labs Inc is $9.00, about 17% above its last closing price of $7.47</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.46</p></td><td><p>-0.48</p></td><td><p>-0.60</p></td><td><p>Missed</p></td><td><p>-24.8</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.53</p></td><td><p>-0.53</p></td><td><p>-0.36</p></td><td><p>Beat</p></td><td><p>31.9</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-3.33</p></td><td><p>-2.08</p></td><td><p>-1.97</p></td><td><p>Beat</p></td><td><p>5.2</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.72</p></td><td><p>-0.72</p></td><td><p>-6.70</p></td><td><p>Missed</p></td><td><p>-828.3</p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated November 5 at 21:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOAGE Labs Inc  expected to post a loss of 58 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOAGE Labs Inc  expected to post a loss of 58 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BIOAGE Labs Inc <bioa.oq> expected to post a loss of 58 cents a share - Earnings Preview </bioa.oq></title></head><body><ul><li><p>BIOAGE Labs Inc <span>BIOA.OQ</span> <span>BIOA.O</span> is expected to  show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2025</p></li><li><p>The Emeryville California-based  company is expected to report revenue of $1.037 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for BIOAGE Labs Inc is for a loss of 58 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 2 \"hold\" and 1 \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for BIOAGE Labs Inc is $9.00, about 17% above its last closing price of $7.47</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.46</p></td><td><p>-0.48</p></td><td><p>-0.60</p></td><td><p>Missed</p></td><td><p>-24.8</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.53</p></td><td><p>-0.53</p></td><td><p>-0.36</p></td><td><p>Beat</p></td><td><p>31.9</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-3.33</p></td><td><p>-2.08</p></td><td><p>-1.97</p></td><td><p>Beat</p></td><td><p>5.2</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.72</p></td><td><p>-0.72</p></td><td><p>-6.70</p></td><td><p>Missed</p></td><td><p>-828.3</p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated November 5 at 21:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL8N3WH379:1","article_id":"2581354701","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581354701","pubTimestamp":1762376782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BIOAGE Labs Inc  expected to post a loss of58cents a share - Earnings Preview BIOAGE Labs Inc BIOA.OQ BIOA.O is expected to  show a rise in quarterly revenue when it reports  results on November 7 (es","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BIOA":"BioAge Labs Inc."},"translate_title":"BIOAGE Labs Inc预计每股亏损58美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9},"content_text":"BIOAGE Labs Inc  expected to post a loss of 58 cents a share - Earnings Preview BIOAGE Labs Inc BIOA.OQ BIOA.O is expected to  show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2025The Emeryville California-based  company is expected to report revenue of $1.037 million, according to the mean estimate from 3 analysts, based on LSEG data.LSEG's mean analyst estimate for BIOAGE Labs Inc is for a loss of 58 cents per share. The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 2 \"hold\" and 1 \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for BIOAGE Labs Inc is $9.00, about 17% above its last closing price of $7.47Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jun. 30 2025-0.46-0.48-0.60Missed-24.8Mar. 31 2025-0.53-0.53-0.36Beat31.9Dec. 31 2024-3.33-2.08-1.97Beat5.2Sep. 30 2024-0.72-0.72-6.70Missed-828.3This summary was machine generated November 5 at 21:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}